We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nestor Health. | LSE:NSR | London | Ordinary Share | GB0006313034 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 109.50 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMNSR
RNS Number : 6140A
Nestor Healthcare Group PLC
03 February 2011
Not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of that jurisdiction
3 February 2011
Recommended cash acquisition of Nestor Healthcare Group plc by Saga Group Limited
Delisting of Nestor Healthcare Group plc Shares
Following an application by Nestor Healthcare Group plc ("Nestor") to the UK Listing Authority, the admission to trading of the Nestor Shares on the London Stock Exchange's main market for listed securities and the admission to listing of the Nestor Shares on the Official List of the UK Listing Authority in each case was cancelled and, consequently, Nestor Shares ceased to be admitted to listing on the Official List of the UK Listing Authority and to trading on the London Stock Exchange with effect from 8.00 a.m. (London time) today.
Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the circular containing the Scheme that was sent to Nestor Shareholders on 10 December 2010.
A copy of this announcement will be available on the Nestor website at www.nestorplc.co.uk by no later than 12 noon on 4 February 2011.
Enquiries
Nestor Tel: +44 (0) 1707 286 817 John Ivers, Chief Executive Martyn Ellis, Group Finance Director Investec (financial adviser to Nestor) Tel: +44 (0) 20 7597 5970 Martin Smith Gary Clarence Cara Griffiths Alex Thomson Citigate Dewe Rogerson (PR advisers to Tel: +44 (0) 20 7638 9571 Nestor) Toby Mountford Ged Brumby
Investec, which is authorised and regulated in the United Kingdom by the FSA, is acting exclusively for Nestor in relation to the Acquisition and will not be responsible to anyone other than Nestor for providing the protections afforded to the clients of Investec, nor for providing advice in relation to the Acquisition or to the matters referred to in this announcement. Neither Investec nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Investec in connection with the Acquisition or this announcement, any statement contained herein or otherwise.
Notice to Overseas Shareholders: The availability of the Acquisition or the distribution of this announcement to Nestor Shareholders who are not resident in the United Kingdom may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Such persons should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. Nestor Shareholders who are in any doubt regarding such matters should consult an appropriate independent professional adviser in the relevant jurisdiction without delay.
This announcement has been prepared in accordance with English law, the Takeover Code and the Listing, Prospectus, Disclosure and Transparency Rules and information disclosed may not be the same as that which would have been prepared in accordance with the laws of jurisdictions outside England.
Notice to US investors in Nestor: The Acquisition relates to the shares of an English company and is being implemented by means of a scheme of arrangement provided for under English company law. A transaction effected by means of a scheme of arrangement is not subject to the tender offer rules under the US Exchange Act of 1934. Accordingly, the Acquisition is subject to the disclosure requirements and practices applicable in the UK to schemes of arrangement which differ from the disclosure requirements of the US tender offer rules. If, in the future, Saga and Acromas exercise its right to implement the Acquisition by way of an Offer, which is to be made into the United States, such Offer will be made in compliance with the applicable US laws and regulations.
This announcement may contain "forward looking statements" concerning Saga, Acromas and Nestor. Generally, the words "will", "may", "should", "continue", "believes", "expects", "intends", "anticipates" or similar expressions identify forward looking statements. The forward looking statements involve risks and uncertainties that could cause actual results to differ materially from those suggested by them. Many of these risks and uncertainties relate to factors that are beyond the ability of Saga, Acromas and Nestor to control or estimate precisely, such as future market conditions and the behaviours of other market participants and therefore undue reliance should not be placed on such statements which speak only as at the date of this announcement. Saga, Acromas and Nestor and their respective affiliates assume no obligation and do not intend to update these forward looking statements, except as required pursuant to applicable law.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFFDFVIVIIL
1 Year Nestor Healthcare Chart |
1 Month Nestor Healthcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions